# An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

> **NCT00398957** · PHASE1 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 32 (actual)

## Conditions studied

- Analgesia

## Interventions

- **DRUG:** OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).

## Key facts

- **NCT ID:** NCT00398957
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1998-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398957, "An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00398957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*